BOSTON SCIENTIFIC CORP (BSX) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BSX - US1011371077 - Common Stock
BSX Key Statistics, Chart & Performance
The current stock price of BSX is 97.64 USD. In the past month the price increased by 5.33%. In the past year, price increased by 2.91%.
BSX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B | ||
| HOLX | HOLOGIC INC | 17.53 | 16.69B |
Related stock screener links
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 53000
Phone: 15086834000
BOSTON SCIENTIFIC CORP / BSX FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX is 97.64 USD. The price decreased by -0.75% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX does not pay a dividend.
What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?
BSX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for BSX stock?
BOSTON SCIENTIFIC CORP (BSX) currently has 53000 employees.
What is the Short Interest ratio of BOSTON SCIENTIFIC CORP (BSX) stock?
The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 1.3% of its float.
BSX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BSX. When comparing the yearly performance of all stocks, BSX turns out to be only a medium performer in the overall market: it outperformed 45.31% of all stocks.
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSX. While BSX has a great profitability rating, there are some minor concerns on its financial health.
BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 2.95. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
BSX Forecast & Estimates
40 analysts have analysed BSX and the average price target is 127.2 USD. This implies a price increase of 30.27% is expected in the next year compared to the current price of 97.64.
For the next year, analysts expect an EPS growth of 22.13% and a revenue growth 20.9% for BSX